Motavizumab for the prevention of respiratory syncytial virus infection in infants

Expert Opinion on Biological Therapy

Volumn 9, Issue 10, 2009, Pages 1335-1345

  Gill, Michelle A ^a   Welliver Sr , Robert C ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bronchiolitis; Monoclonal antibody; Motavizumab; Palivizumab; Respiratory syncytial virus

Indexed keywords

1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; ALN RSV 01; ANTIVIRUS AGENT; BRONCHODILATING AGENT; BTA 9881; CORTICOSTEROID; DEOXYRIBONUCLEASE; HELIOX; HNK 20; IMMUNOGLOBULIN; MONTELUKAST; MOTAVIZUMAB; NITROUS OXIDE; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RETINOL; RIBAVIRIN; RSV 604; SMALL INTERFERING RNA; SURFACTANT; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANNULAR ERYTHEMA; BRONCHIOLITIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LIVER FUNCTION TEST; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SIDE EFFECT; SKIN ALLERGY; THROMBOSIS; URTICARIA; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RNA, SMALL INTERFERING; VIRAL VACCINES;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 70349376986     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903287499     Document Type: Review

References (65)

1. Heilman CA. From the national institute of allergy and infectious diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990;161(3):402-406
2. Respiratory syncytial virus activity-United States, 1999-2000 season. MMWR Morb Mortal Wkly Rep 2000;49(48):1091-1093
3. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child (1960) 1986;140(6):543-546
4. Falsey AR, Formica MA, Hennessey PA, et al. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173(6):639-643 (Pubitemid 43363805)
5. Ackerman BD. Acute bronchiolitis: a study of 207 cases. Clin Pediatr (Phila) 1962;1:75-81
6. Chanock RM, Kim HW, Vargosko AJ, et al. Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 1961;176:647-653
7. Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991;133(11):1135-1151
8. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137(6):865-870
9. Glezen WP, Paredes A, Allison JE, etal. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98(5):708-715 (Pubitemid 11070320)
10. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002;21(7):629-632
11. Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001;183(1):16-22
12. Acute Respiratory Infections (Update 2009). World Health Organization: Initiative for Vaccine Research (IVR). Geneva, Switzerland; 2009. Available from: http://www.who.int/vaccine-research/diseases/ari/en/.
13. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360(6):588-598
14. Pelletier AJ, Mansbach JM, Camargo CA Jr. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics 2006;118(6):2418-2423 (Pubitemid 46397582)
15. Yusuf S, Piedimonte G, Auais A, et al. The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect 2007;135(7):1077-1090 (Pubitemid 47487593)
16. Dobson JV, Stephens-Groff SM, McMahon SR, etal. The use of albuterol in hospitalized infants with bronchiolitis. Pediatrics 1998;101(3 Pt 1):361-368
17. Corneli HM, Zorc JJ, Mahajan P, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007;357(4):331-339 (Pubitemid 47124133)
18. Levine DA, Platt SL, Dayan PS, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. Pediatrics 2004;113(6):1728-1734 (Pubitemid 38697983)
19. Hammer J, Numa A, Newth CJ. Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. J Pediatr 1995;127(3):485-490
20. Schuh S, Canny G, Reisman JJ, et al. Nebulized albuterol in acute bronchiolitis. J Pediatr 1990;117(4):633-637
21. Gadomski AM, Lichenstein R, Horton L, et al. Efficacy of albuterol in the management of bronchiolitis. Pediatrics 1994;93(6 Pt 1):907-912
22. Dabbous IA, Tkachyk JS, Stamm SJ. A double blind study on the effects of corticosteroids in the treatment of bronchiolitis. Pediatrics 1966;37(3):477-484
23. Roosevelt G, Sheehan K, Grupp-Phelan J, et al. Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet 1996;348(9023):292-295 (Pubitemid 26254628)
24. Leer JA Jr, Green JL, Heimlich EM, et al. Corticosteroid treatment in bronchiolitis. A controlled, collaborative study in 297 infants and children. Am J Dis Child (1960) 1969;117(5):495-503
25. Flores G, Horwitz RI. Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis. Pediatrics 1997;100(2 Pt 1):233-239 (Pubitemid 27328202)
26. American academy of pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis management of bronchiolitis. Pediatrics 2006;118(4):1774-1793
27. Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007;195(8):1126-1136 (Pubitemid 46543443)
28. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983;308(24):1443-1447
29. Rodriguez WJ, Hall CB, Welliver R, et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 1994;125(1):129-135 (Pubitemid 24225195)
30. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325(1):24-29
31. Moler FW, Bandy KP, Custer JR. Ribavirin therapy for acute bronchiolitis: need for appropriate controls. J Pediatr 1991;119(3):509-510
32. Safety Study of Oral BTA9881 to Treat RSV Infection. 2007 Available from: http://clinicaltrials.gov/ct2/show/NCT00504907 [Cited 18 July 2007]
33. Cianci C, Yu KL, Combrink K, et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 2004;48(2):413-422 (Pubitemid 38141696)
34. Bonfanti JF, Roymans D. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel 2009;12(4):479-487
35. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89(4):422-434
36. Tristram DA, Welliver RC, Mohar CK, et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993;167(1):191-195
37. Gonzalez IM, Karron RA, Eichelberger M, et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 2000;18(17):1763-1772 (Pubitemid 30122838)
38. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993;329(21):1524-1530
39. Welliver RC. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection. Semin Perinatol 1998;22(1):87-95 (Pubitemid 28162332)
40. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102(3 Pt 1):531-537 (Pubitemid 28409250)
41. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-540
42. Pickering LK, Baker CJ, Long SS, McMillan JA, editors, Red Book: 2009 Report of the Committee on Infectious Diseases. 28th edition. Elk Grove Villiage, IL: American Academy of Pediatrics; 2009
43. Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 1997;100(6):937-942
44. Saez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004;23(8):707-712 (Pubitemid 39063284)
45. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007;368(3):652-665 (Pubitemid 46527610)
46. Abarca K, Jung E, Fernandez P, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J 2009;28(4):267-272
47. Carbonell X, Losonsky GA, Micki H, Edward C. Phase3 trial of motavizumab (MEDI-524), an enhanced potency respiratory syncytial virus (RSV) specific monoclonal antibody (Mab) for the prevention of serious RSV disease in high risk infants. Abstract presented at annual PAS meeting in Toronto, Canada. E-PAS2007:6182209 2007 May 1-4, 2007
48. HPTN 057 SSP Manual, Section 11. Adverse Event Reporting and Safety Monitoring. 2007:1-11. Available from: http://www.hptn.org/web%20documents/ HPTN057/SSP/HPTN057Section11AEsv3.0FINAL.pdf
49. Wilkesmann A, Ammann RA, Schildgen O, et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 2007;26(6):485-491 (Pubitemid 46847308)
50. Chanock RM, Parrott RH, Connors M, et al. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics 1992;90(1 Pt 2):137-143
51. Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002;196(6):859-865
52. Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976;134(3):211-217
53. Meert KL, Sarnaik AP, Gelmini MJ, Lieh-Lai MW. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. Crit Care Med 1994;22(4):566-572
54. Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch Pediatr Adolesc Med 1996;150(9):942-947
55. Merkus PJ, de Hoog M, van Gent R, de Jongste JC. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J 2001;18(4):734-737
56. Hollman G, Shen G, Zeng L, et al. Helium-oxygen improves Clinical Asthma Scores in children with acute bronchiolitis. Crit Care Med 1998;26(10):1731-1736 (Pubitemid 28467683)
57. Liet JM, Millotte B, Tucci M, et al. Noninvasive therapy with helium-oxygen for severe bronchiolitis. J Pediatr 2005;147(6):812-817 (Pubitemid 41774839)
58. Broughton S, Greenough A. Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity. Expert Opin Pharmacother 2003;4(10):1801-1808 (Pubitemid 37322364)
59. Patel NR, Hammer J, Nichani S, et al. Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis. Intensive Care Med 1999;25(1):81-87 (Pubitemid 29126719)
60. Neuzil KM, Gruber WC, Chytil F, et al. Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections. Antimicrob Agents Chemother 1995;39(5):1191-1193
61. Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998;178(6):1555-1561 (Pubitemid 28558122)
62. Mandelberg A, Tal G, Witzling M, et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest 2003;123(2):481-487 (Pubitemid 36269434)
63. Kuzik BA, Al-Qadhi SA, Kent S, et al. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr 2007;151(3):266-270, 70 e1 (Pubitemid 47284136)
64. Tibby SM, Hatherill M, Wright SM, et al. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2000;162(4 Pt 1):1251-1256 (Pubitemid 30826136)
65. Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008;178(8):854-860